OHSU researchers identify key trigger behind brain disorder often mistaken for mental illness

A new OHSU study shows how the immune system can quietly disrupt brain function — and why the disease is often hard to ...
Managed Healthcare Executive

Glutamate levels associated with psychosis onset in treatment-naive patients, study finds

Glutamate levels increase in early psychosis but normalize over time, challenging established perspectives on schizophrenia progression. The study involved treatment-naive patients, isolating natural ...

Gilgamesh Pharma Announces Positive Topline Phase 2a Results for Blixeprodil (GM-1020) in Major Depressive Disorder

Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced positive topline results from its Phase 2a study of blixeprodil (GM-1020).

Rare 'Brain on Fire' disorder highlighted in Netflix film may soon have new treatments

No standard treatments for the sometimes deadly disorder have been developed, but that may change due to the newly published ...
Hoodline

Portland Lab Nails the 'Brain on Fire' Culprit in Stunning Microscopic Detail

New OHSU study maps antibody "hot spots" behind anti‑NMDAR encephalitis. Could change diagnosis and treatment.
Pharmabiz

GRIN Therapeutics begins patient dosing in global phase 3 Beeline trial of investigational radiprodil for GRINRelated neurodevelopmental disorder

GRIN Therapeutics begins patient dosing in global phase 3 Beeline trial of investigational radiprodil for GRINRelated neurodevelopmental disorder: New York Monday, January 12, 202 ...

GRIN Therapeutics Announces First Patient Dosed in Global Phase 3 Beeline Trial of Investigational Radiprodil for GRIN-Related Neurodevelopmental Disorder

GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies for serious neurodevelopmental disorders, today announced that it has dosed the first patient in its global ...